Skip to content


  • Short report
  • Open Access

Clinical significance of 4 patients with chronic hepatitis B achieving HBsAg clearance by treated with pegylated interferon alpha-2a for less than 1 year: a short report

Virology Journal20096:97

  • Received: 24 April 2009
  • Accepted: 08 July 2009
  • Published:


We report 4 chinese patients with hepatitis B e antigen-positive chronic hepatitis B achieving clearance of HBsAg by using pegylated interferon alpha-2a for less than 1 year, to provide one clinical clue for the treatment of chronic hepatitis B.


  • Entecavir
  • HBeAg Seroconversion
  • Sequential Therapy
  • Pegasys
  • HBsAg Clearance


Chronic infection with Hepatitis B virus(HBV) is a major global health problem, affecting 350–400 million people worldwide [1, 2]. Patients who have HBV infection with positivity for hepatitis B e antigen(HBeAg) and persistently active disease have increased risks for progressive disease leading to liver cirrhosis and hepatocellular carcinoma[3]. Therefore, for patients with HBeAg positive chronic hepatitis B(CHB), anti-viral therapy is most important if they have indications for treatment. The end points to assess efficacy of therapy include: reduction of serum HBV DNA to the undetectable level, normalization of alanine aminotransferase(ALT) levels, HBeAg seroconversion and an improvement of liver disease at histology[4]. But it is gradually thought that the ultimate therapeutic goal of anti-HBV therapy should furthermore make patients achieve clearance of hepatitis B surface antigen(HBsAg) or even HBsAg seroconversion [5, 6]. In view of current anti-HBV drugs, however, it is extremely difficult to implement this goal. Nevertheless, on condition that there is a treatment with effective anti-viral drugs and appropriate therapeutic schemes, some patients may still be able to achieve it.



All 4 patients aged from 14 to 49 yrs-old, including 3 males and 1 female, had suffered from CHB for 1 to 3 years with the sera profile of HBeAg, HBsAg positive, and HBV DNA leveled from 2.71 × 106 copies/mL to 5.00 × 107 copies/mL. They came to our hospital for pegylated interferon alpha-2a(Pegasys) treatment from March 2006 to Ten 2007. All of them had neither complications nor other accompanying diseases, also with no history of anti-HBV drug use.

Methods of treatment

Classification of methods

Pegasys monotherapy Case 1 was treated with pegasys at a dose of 135 ug intracutaneously one time per week(for her age was below 18). Case 2 was treated with pegasys at a dose of 180 ug intracutaneously one time per week.

Sequential therapy As both leucopenia and thrombocytopenia occurred in case 3 and case 4 during the treatment of pegasys, we adopted sequential therapy with pegasys and entecavir(Baraclude). Pegasys was administered at a dose of 180 ug intracutaneously one time per week. Baraclude was administered at a dose of 0.5 mg orally one time per day.

Periodic monitoring of anti-viral therapy

Leukocyte and platelet counts, serum HBV DNA and ALT were detected once every month. HBV markers(HBsAg and anti-HBs, HBeAg and anti-HBe, anti-HBc) were detected once every three months. Among them, serum HBV DNA was arrayed by fluorescent quantitative PCR and HBV markers were arrayed by ELISA.


Therapeutic efficacy

Within less than 1 year, serum HBV DNA loss, ALT normalization, HBeAg seroconversion, HBsAg clearance occurred in the 4 patients treated with either pegasys monotherapy (the longest period of treatment was 40 weeks, the shortest period of treatment was 20 weeks) or sequential therapy with pegasys and baraclude (the longest period of treatment with pegasys was 24 weeks, the shortest period of treatment with pegasys was 16 weeks). Among them, the latest time when HBsAg clearance occurred (in case 4) was at week 44, and the earliest time when HBsAg clearance occurred (in case 1) was at week 17. Furthermore, HBsAg seroconversation occurred in case 1 at week 20, which is sustained positive in 48 weeks follow-up, while HBsAg negative also kept steady in case 2, case 3, case 4 in 60 weeks follow-up, 60 weeks follow-up, 72 weeks follow-up, respectively. All of them are kept under observation until now. The Variations of sera HBV DNA, ALT and HBV markers in the four patients are outlined in Table 1.
Table 1

Therapeutic efficacy of pegasys in 4 patients with chronic hepatitis B


Case 1

Case 2

Case 3

Case 4











Course of diseasea(yr)








Sequential therapy

Sequential therapy

Course of treatmentb(wk)





HBV DNA undetectablec

Week 14

Week 16

Week 20

Week 14

ALT normalization

Week 36

Week 26

Week 23

Week 14

HBeAg seroconversion

Week 16

Week 22

Week 23

Week 38

HBsAg clearance

Week 17

Week 40

Week 24

Week 44

HBsAg seroconversion

Week 20




yr, year; wk, week; ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus.

a interval between the first time when HBsAg-positive was detected and the date before treatment.

b cumulate course between the first day of anti-HBV treatment and the date when complete response occurred.

c HBV DNA<1000 copies/ml.

Adverse events

During the course of pegasys treatment, apparent reduction of leukocyte and platelet counts had occurred in 2 patients (case 3 and case 4) at week 4 and week 10 of therapy respectively, but returned to baseline levels one month after sequential therapy was adopted (pegasys was paused temporarily, baraclude was administered until the leukocyte and platelet counts recovered). There were no other remarkable adverse events in all the four cases during the total course of anti-viral therapy.


The aims of treatment for CHB are to achieve sustained suppression of HBV replication, thereby inducing remission of liver diseases and interrupting progression to liver cirrhosis or hepatocellular carcinoma[7]. Pegylated interferon alpha-2a is created by attaching a large, branched, 40-kD polyethylene glycol molecule to interferon alfa-2a[8], This allows for convenient once-weekly dosing, with effective serum levels maintained throughout the dosing interval[9]. It could efficaciously inhibit the replication of HBV and help eradicate HBV infectious hepatocytes by dual anti-viral and immunomodulatory mode of action[10]. In contrast to nucleoside analogues, pegylated interferon alpha-2a has a higher rate of HBeAg seroconversion, lower rate of relapse after treatment cessation, moreover, it has not been observed to induce mutation of HBV [11, 12]. However, it has a few adverse events such as transient flu-like symptoms, depression and abnormal blood counts [13, 14]. In this study, both leucopenia and thrombocytopenia had been observed in case 3 and case 4, so we adopted sequential therapy with pegasys and baraclude (one kind of nucleoside analogues). The results showed that their leukocyte and platelet counts gradually returned to the baseline levels one month after pegasys was paused and baraclude was administered sequentially, then we continued the administration of pegasys. For the reason that sequential therapy could effectively evade the inherent adverse events of pegasys and meanwhile, nucleoside analogues could keep sustained suppression of HBV during the time when pegasys is paused, so the advantageous efficacy of pegasys could be brought into play as much as possible.

By analyzing above materials, we had observed one phenomenon that the clearance of HBsAg occurred in the 4 patients not very long(1 wk, 18 wks, 1 wk and 6 wks, respectively) after they had achieved HBeAg seroconversion. This may imply that pegylated interferon alpha-2a probably plays an important role in helping clear HBsAg by means of activating the host immune reaction. Additionally, ALT levels in the 4 patients were elevated during treatment but gradually normalized at the end of therapy, they also had no clinical symptoms. Considering that pegylated interferon alpha-2a takes effect by improving the host immune function, we suppose the occurrence of transient elevated ALT might be a reflection of the course during which HBV infectious hepatocytes are being eradicated.

Although limited case numbers are reported in this article and more patients need to be included for further study, one certain clue, which can be provided to clinical doctors, is that some patients with HBeAg-positive CHB could probably be expected to achieve the ideal therapeutic goal of HBeAg seroconversion, HBsAg clearance and even HBsAg seroconversion if they are treated with effective anti-viral drugs and appropriate therapeutic schemes.


Based on our clinical observation, either pegasys monotherapy or sequential therapy with pegasys and baraclude is efficacious and relatively safe for treating patients with CHB.



We are grateful to Ping Feng for her helpful comments and suggestions.

Authors’ Affiliations

Department of Infectious Diseases, Nanshan Affiliated Hospital of Guangdong Medical College, Shenzhen, 518052, China
Center of Infectious Diseases, National Key Laboratory of Biotherapy for Human Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan Province, 610041, China


  1. Lai CL, Ratziu V, Yuen MF, Poynard T: Viral hepatitis B. Lancet 2003, 362: 2089-94. 10.1016/S0140-6736(03)15108-2View ArticlePubMedGoogle Scholar
  2. Mohanty SR, Kupfer SS, Khianiv : Treatment of chronic hepatitis B. Nat clin pract Gastroenterol Hepato 2006, 3: 446-458. 10.1038/ncpgasthep0550View ArticleGoogle Scholar
  3. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS, Chen CJ: Taiwan Community-Based Cancer Screening Project Group. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002, 347: 168-74. 10.1056/NEJMoa013215View ArticlePubMedGoogle Scholar
  4. Sherman M: Personal view: the management of chronic hepatitis B infection. Aliment Pharmacol Ther 2006, 23: 857-869. 10.1111/j.1365-2036.2006.02840.xView ArticlePubMedGoogle Scholar
  5. Papatheodoridis GV, Manesis E, Hadziyannis SJ: The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001, 34: 306-13. 10.1016/S0168-8278(00)00094-5View ArticlePubMedGoogle Scholar
  6. EASL International Consensus Conference on Hepatitis B: 13–14 September, 2002 Geneva, Switzerland: consensus statement(long version). J Hepatol 2003,39(Suppl 1):S3-S25.Google Scholar
  7. Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology 2007, 45: 507-39. 10.1002/hep.21513View ArticlePubMedGoogle Scholar
  8. Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ, Porter JE, Ehrlich GK, Pan W, Xu ZX, Modi MW, Farid A, Berthold W, Graves M: Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001, 12: 195-202. 10.1021/bc000082gView ArticlePubMedGoogle Scholar
  9. Perry CM, Jarvis B: Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C. Drugs 2001, 61: 2263-88. 10.2165/00003495-200161150-00013View ArticlePubMedGoogle Scholar
  10. Craxi A, Cooksley WG: Pegylated interferons for chronic hepatitis B. Antiviral Res 2003, 60: 87-89. 10.1016/j.antiviral.2003.08.015View ArticlePubMedGoogle Scholar
  11. Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, Chutaputti A, Chang WY, Zahm FE, Pluck N: Peginterferon alpha-2a(40 KD): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepatitis 2003, 10: 298-305. 10.1046/j.1365-2893.2003.00450.xView ArticleGoogle Scholar
  12. Tillmann HL: Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol 2007, 13: 125-140.PubMed CentralView ArticlePubMedGoogle Scholar
  13. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Button P, Pluck N: Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004, 351: 1206-17. 10.1056/NEJMoa040431View ArticlePubMedGoogle Scholar
  14. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N: Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005, 352: 2682-95. 10.1056/NEJMoa043470View ArticlePubMedGoogle Scholar


© Yang and Zhao; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.